Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Must Reads In FDA Actions
FDA Actions for January/February 2019
FDA Approves Jeuveau for Glabellar Lines, FirstWord Pharma news release; 2019 Feb 1
FDA Actions for November/December 2018
FDA Approves Hyrimoz for Plaque Psoriasis, Sandoz news release; 2018 Oct 31
FDA Actions for September/October 2018
FDA Approves Seysara for Severe Acne Vulgaris, Paratek Pharmaceuticals, Inc. news release; 2018 Oct 2
FDA Approves Nuzyra for Acute Skin Infections, Paratek Pharmaceuticals, Inc. news release; 2018 Oct 2
Psoriasis Treatment Receives Tentative FDA Approval, Bausch Heath news release; 2018 Oct 8
FDA Approves Libtayo for Metastatic cSCC, Sanofi news release; 2018 Sep 28
FDA Actions for July/August 2018
FDA Approves Qbrexza for Excessive Armpit Sweating, Dermira Inc. news release; 2018 Jun 29
FDA Approves Drug Combination for Melanoma, Array BioPharma news release; 2018 Jun 27
FDA Actions for May/June 2018
FDA Approves Rituxan for Pemphigus Vulgaris, Genentech Web site; 2018 Jun 7
FDA Extends Label for Cimzia for Plaque Psoriasis, UCB news release; 2018 May 29
FDA Updates Label for Taltz for Genital Psoriasis, PharmaLive news release; 2018 May 22
FDA Approves Restylane Lyft for Back of Hands, FirstWord Pharma news release; 2018 May 21
FDA Approves Tafinlar-Mekinist Combo for Melanoma, Novartis news release; 2018 Apr 30